Lisa M Frenkel, MD

Lisa M Frenkel, MD

Infectious Disease and Virology

On staff since March 1995

Academic Title: Professor, Pediatrics and Laboratory Medicine and Pathology

Research Center: Center for Global Infectious Disease Research

  • Dr. Lisa Frenkel is an internationally recognized expert on HIV and infectious disease. She is Co-Director of the Center for Global Infectious Disease Research at Seattle Children's Research Institute; Professor of Pediatric Infectious Diseases, Laboratory Medicine and Pathology at the University of Washington; and co-director of Seattle Children's Pediatric Infectious Diseases and Virology Clinics.

     

    Professor of Pediatrics and Laboratory Medicine and Pathology, Member Division of Infectious Diseases and Co-Director of Seattle Children’s Research Institute’s (SCRI) Center for Global Infectious Disease Research (CGIDR).

    EDUCATION:

    1976                   Universidad de Costa Rica, San Jose

    1977                   B.A., Kansas University, Lawrence, Kansas

    1981                   M.D., Kansas University Medical School, Kansas City, Kansas

    POSTGRADUATE TRAINING:

    1981-1984          Pediatric Residency, University of California, Los Angeles, California

    1984-1987          Infectious Disease Fellowship, University of California, Los Angeles, California

    FACULTY POSITIONS HELD (since 1999):

    1999-present      Director, HIV-1 Drug Resistance Testing for University WA Clinical Laboratory

    2003-present      Professor of Pediatrics, University of Washington, Seattle Children’s Hospital, Seattle, Washington

    2003-present      Professor of Laboratory Medicine, University of Washington, Seattle, Washington

    2010-present      Affiliate Investigator, Vaccine and Infectious Disease Division of the Fred Hutchinson Cancer Research Center, Seattle, Washington

    • Related Pages

    • Frenkel Lab

      Frenkel Lab

      The Frenkel Lab aims to: understand the mechanisms that allow HIV to persist during antiretroviral therapy; develop practical, affordable tests to detect drug-resistant HIV; make insights into reservoirs of drug-resistant HIV and illuminate the pathogenesis of HIV-related diseases.

    • My Bibliography - NCBI

      For a list of my publications, please access MyBibliography.

    Be the first to recommend Lisa M Frenkel, MD
  • Award Name Award Description Awarded By Award Date
    Chair, NIH, Special Emphasis Panel 2018
    Top Meeting Participant, XXXVII International Workshop on HIV & Hepatitis Virus Drug Resistance 2018
    Awarded "AAAS Fellow" distinction, American Association for Advancement of Science (AAAS) 2017
    IDWeek 2016 Diagnostics Abstract Award, given to best abstracts submitted in diagnostics 2016
    Reviewer of application scoring across Integrated Review Groups for NIH Center for Scientific Review 2015 - 2016
    Best Poster of Meeting, International Workshop on HIV and Hepatitis Virus Drug Resistance 2013
    Best Poster of Meeting, International Workshop on HIV & Hepatitis Virus Drug Resistance 2013
    Outstanding Mentor Award of 2011, University of WA, Dept Pediatrics 2011
    Member, (extended 4y + 2yr) NIH-NIAID AIDS Research Review Committee (AIDSRRC) 2011 - 2013
    Extraordinary Professor in the Department of Immunology, Faculty of Health Sciences, University of Pretoria 2010 - 2012
    Member, NIH-NIAID AIDS Research Review Committee (AIDSRRC) 2007 - 2011
    Member, 4-year term, NIH AARR-3/ADDT Study Section 2002 - 2006
    1st William F. Friedman Lectureship, UCLA 1994
    Russel Haden Medal for medical student research Kansas University 1978
  • Presentations Title Event Location Date
    Invited Speaker, UW Department of Global Health, Pathobiology Interdisciplinary Program, "Reconsidering HIV drug resistance: When is it a problem and can it be avoided?" Seattle, WA 2017
    Invited Speaker, Seattle Childrens Hospital, UW Pediatrics, ID Adult Fellows, "Neonatal HSV," Seattle, WA 2017
    Invited Speaker, NIH Consultation on Global Trends of HIV Drug Resistance Meeting, Rockville, Maryland 2016
    Invited Speaker, Vaccine and Infectious Disease Division of the Fred Hutchinson Cancer Research Center, "How are HIV reservoirs sustained during antiretroviral treatment (ART)?" Seattle, Washington 2015
    Invited Speaker, NIAID-NICHD, IMPAACT Leadership Meeting, on "HIV Virology: Laboratory priorities for future," Washington, DC 2015
    Invited Speaker, Antiretroviral Treatment in Children International Course HIV: Pathogenesis, Prevention and Treatment2015: Toward to HIV Cure Lima, Peru 2015
    Invited Speaker, International Course HIV: Pathogenesis, Prevention and Treatment2015: Toward to HIV Cure, "Antiretroviral Treatment in Children," Lima, Peru 2015
    Invited Speaker, Cape Town HVTN Immunology Laboratorys Next Generation Sequencing in Clinical Vaccine Trials Workshop, Cape Town, South Africa 2015
    Seattle Childrens Hospital, Pediatric Departmental Grand Rounds Speaker 2014
    Invited Speaker, Conference on Cell and Gene Therapy for HIV Cure 2014 FHCRC Seattle, WA 2014
    Use of point mutation assays for resistance testing in Kenya - challenges and benefits Invited Speaker, Collaborative Meeting on Defining Key HIV-1 Mutations for Determining ARV Resistance in Low and Middle Income Countries Cape Town, South Africa 2014
    Invited Speaker, Rapid inexpensive point-of-care assays Global WACh Seminar Series: 2014
    Invited Speaker, UCLA, Pediatric Departmental Grand Rounds 2014
    Invited Speaker, Conference on Cell and Gene Therapy for HIV Cure 2014, FHCRC, Seattle 2014
    Invited Speaker, Pediatric Departmental Grand Rounds Speaker Seattle Children's Hospital Seattle, WA 2014
    Invited Speaker, Pediatric Departmental Grand Rounds UCLA 2014
    Strategies Towards HIV CURE for Infected Children Washington, DC 2013
    HIV Reservoirs and Viral Eradication Transformative Science Group (Cure TSG) of the AIDS Clinical Trials Group 2013
    Invited Speaker, HIV Dynamics and Evolution Meeting Asheville, North Carolina 2012
    Invited Speaker, HIV Pathogenesis, Prevention and Treatment 2012 Lima, Peru 2012
    Invited Speaker, XII Congreso de Enfermedades Infecciosas y Tropicales Lima, Peru 2011
    Invited Speaker, XII Congreso de Enfermedades Infecciosas y Tropicales, Lima, Peru 2011
    Invited Speaker, NIH US-Japan, HIV Resistance Meeting, Singapore 2010
    Invited Speaker, 2nd Canada-Colombia Collaborative Research Wkshp HIV Cali, Colombia 2010
    Invited Speaker, 5th Annual Research Symposium Seattle Childrens Research Institute 2010
    Invited Speaker, 5th Annual Research Symposium, Seattle Children’s Research Institute 2010
    Invited Speaker, 2nd Canada-Colombia Collaborative Research Wkshp HIV, Cali, Colombia 2010
    Invited Speaker, HIV Pathogenesis, Prevention and Treatment 2010 Lima, Peru 2010
    Invited Speaker, NIH US-Japan, HIV Resistance Meeting Singapore 2010
    Invited Speaker, HIV Pathogenesis, Prevention and Treatment 2010. Lima, Peru 2010
    Invited Speaker, XVIII Curso Internacional Enfoque Global en el Cuidado de la Salud Peru 2008
    Invited Speaker, Seattle Biomedical Research Institute Seattle, WA 2008
    Invited Speaker, African International Conference on Immunity, Vic Falls, Zimbabwe 2007
    Invited Speaker, 5th Annual Western Regional International Health Conference UW 2007
    Invited Speaker, International Course: HIV, pathogenesis, prevention and treatment Peru 2007
    Invited Speaker, "Scaling Up and Optimizing HIV Treatment and Care in Asia" Thailand 2006
    Invited Speaker, Laboratory Quality Assurance and Capacity Building for HIV Research in Zimbabwe University of Zimbabwe, Harare Feb. 7, 2005 - Feb. 9, 2005
    Invited Speaker, 2nd Workshop on HIV Persistence St Martin 2005
    Invited Speaker. 3rd Annual Western Regional International Health Conference, February 20, Invited Speaker. 3rd Annual Western Regional International Health Conference, February 20, University of Washington, Seattle 2005
    Invited, American Association of Clinical Chemistry Annual Meeting 2004, Edutrak "The Clinical Impact of Viral Mutations" Los Angeles July 2004
    "HIV-1 Pathogenesis" and "Pediatric HIV-1 Disease and Treatment" Kenya: Fogarty IARTP Course: Principles of HIV Care and Research Jan. 19, 2004 - Jan. 23, 2004
    Testing for HIV-1 Drug Resistance Using Filter Paper Specimens, Manuscript Preparation, Drug-Resistance in Mother-to-Child Transmission of HIV-1 India: 4th International AIDS India Conference (3 lectures) Nov. 7, 2003 - Nov. 11, 2003
    2003 Invited, International Course on HIV-1 Pathogenesis, Prevention and Treatment Lima, Peru 2003
    Detection of HIV-1 Resistance to Antiretrovirals using the Oligonucleotide Ligation Assay; Centers for Disease Control and Prevention, Invited Speaker, Surveillance of Antiretroviral Drug Resistance Atlanta, GA 2003
    Invited Speaker, 8th International Congress of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Basel, Switzerland 2003
    Invited Speaker, 9th International Workshop on Virus Evolution and Molecular Epidemiology, Stanford University Palo Alto, CA 2003
    Visiting Professor, Childrens Hospital Washington DC 2003
    Invited Speaker, Challenges in Drug-resistance PACTG San Diego, CA 2002
    Invited Faculty, Course on MTCT of HIV Chennai, India 2002
    "Survivors of Childhood Disease: New Challenges for Clinicians." Visiting Professor, University of Texas in San Antonio 2002
    Invited, NIH-Caribbean Workshop on HIV/AIDS San Juan, Puerto Rico 2002
    Invited Speaker, 8th HIV Dynamics and Evolution International Discussion Paris, France 2001
    Invited Speaker, IDSA San Francisco, CA 2001
    Invited Speaker, Pediatric HIV-1 Update London, England 2000
    Invited Speaker, Thai Physicians of America Conf Chiang Mai, Thailand 2000
    Invited Speaker, IDSA New Orleans, LA 2000
    Invited Speaker, HIV-1 Symposia Bangkok, Thailand 2000
    Invited Speaker, HIV-1 Update Rio de Janeiro, Brazil 1999
    Invited Speaker, Meet-the-Experts: Perinatal HIV Transmission, ICAAC 1999
    Invited Speaker, 2nd Annual Chilean Conference on Antiretroviral Therapy 1999
    Invited Speaker, IX Peruvian Course of STD/HIV Lima, Peru 1999
    Invited Speaker, VIII Peruvian Course of STD/HIV Lima, Peru 1997
    Invited Speaker, 3rd Bi-Annual Latin American Conference on HIV/AIDS 1997
  • Grant Title Grantor Amount Award Date
    "Defining HIV reservoirs that rebound following suspension of ART" - R01 AI134419 (MPI: Frenkel, Vandekerckhove) NIH $488,161 annual direct costs Aug. 17, 2017 - July 31, 2022
    "Mechanisms controlling the persistence of infectious HIV reservoirs in children" - R01 HD094719 (PI: Frenkel) NIH $273,653 annual direct costs Aug. 1, 2017 - June 30, 2022
    "HIV integration-mediated modulation of immune regulation in HPV-associated cancers" - R01 CA206466 (MPI: Casper, Frenkel) NIH/NCI $572,651 annual direct costs Sept. 1, 2016 - Aug. 31, 2021
    "Role of proviral loci in HIV latency" R01 AI125026 (PI: Mullins) NIH $112,281 subaward annual direct costs Aug. 11, 2016 - July 31, 2020
    "Cell and Gene Therapy for HIV Cure: Therapeutic Vaccine Focus" - UM1 AI126623 (PI: Kiem) NIH $74,033 subaward annual direct costs July 1, 2016 - June 30, 2021
    "Defining Critical Events in Early HIV Infection: Effects of Alcohol and Early ART" - R01 DA040532 NIH $103,774 subaward annual direct costs June 1, 2016 - May 31, 2020
    "P1066" - MK-0518-022 (Brooks Jackson) Johns Hopkins University $11,447 annual direct costs Jan. 1, 2015 - Dec. 31, 2015
    Administrative Supplement (PEPFAR) - R01 AI100037 NIH $436,863 annual direct costs July 15, 2014 - May 31, 2016
    "Evaluation of mHealth strategies to optimize adherence and efficacy of PMTCT/ART" - R01 HD080460 (PI: John-Stewart) NIH $18,795 subcontract annual direct costs May 1, 2014 - April 30, 2019
    "A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART" - R01 AI110375 NIH $250,000 annual direct costs May 1, 2014 - April 30, 2019
    "Mechanisms of Formation and Persistence of Active HIV Reservoirs" - R01 AI111806 (PI: Mullins) NIH $127,030 subcontract annual direct costs April 1, 2014 - Feb. 28, 2019
    "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group" Virology Lab - UM1 AI106716 (PI: Aldrovandi) NIH $102,272 subaward annual direct costs Jan. 1, 2014 - Nov. 30, 2020
    “University of Washington Center for AIDS Research” (CFAR) NIH $11,716 June 2013 - May 2019
    "Detection of HIV drug resistance mutations using highly multiplexed ligation/qPCR assays" NIH March 31, 2013 - April 1, 2014
    "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group" NIH Sept. 1, 2012 - Dec. 31, 2013
    "Quantification and Dynamics of HIV-1 Drug-Resistant Mutants by Pyrosequencing" NIH July 1, 2009 - June 30, 2013
    "Effect of Lactobacillus on Genital HIV-1 RNA and DNA Shedding in Women" NIH Sept. 30, 2008 - Aug. 31, 2010
    "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group" NIH July 1, 2006 - May 31, 2013
    "Etiology of Mastitis in HIV-1 Infected Women" NIH Aug. 15, 2005 - July 31, 2009
    "Reservoirs of Drug-Resistant HIV-1" NIH March 1, 2005 - Feb. 28, 2012
    "Does HIV Continue to Replicate in Lung Macrophages of Children on Effective Therapy?" The Foster Foundation Jan. 1, 2005 - Dec. 31, 2009
    "Reservoirs of drug-resistant HIV-1" NIAID-NIH May 1, 2004 - April 30, 2006
    "Pediatric HIV Clinical Trials Network" Nov. 1, 2003 - Oct. 31, 2008
    "Immunology and Molecular Virology of Acute HIV Infection; Core C: Specimen and Repository" NIH Sept. 30, 2003 - March 31, 2008
    "Adaptation of an OLA for detection of drug-resistant HIV-1 mutants to non-B subtypes" NIH; Center for AIDS Research March 1, 2003 - Feb. 29, 2004
    "HIV Pathogenesis and Shedding" NIH Sept. 15, 2002 - Aug. 31, 2006
    "A pilot study to evaluate a novel method to quantify mitochondrial integrity of leukocytes and red blood cells in cord and peripheral blood." Bristol Meyer Squibb April 1, 2002 - Dec. 31, 2003
    "Immunization by HIV Exposure During Chemoprophylaxis" NIH Sept. 1, 2001 - Sept. 29, 2009
    "Prevention of HIV resistance to nevirapine in pregnancy." Fogarty International Center, NIH July 1, 2001 - Sept. 30, 2008
    "Womens HIV-1 Pathogenesis Program Project" NIH April 1, 2001 - March 31, 2008
    "Viral Lymphocyte Dynamics in Children" The Foster Foundation Jan. 1, 2001 - Dec. 31, 2001
    "Children Affected by AIDS Foundation" Jan. 1, 2001 - Dec. 31, 2001
    "Pediatric AIDS Foundation Emergency Funds." Elizabeth Glaser Pediatric AIDS Foundation Jan. 1, 2001 - Dec. 31, 2001
    "Viral Lymphocyte Dynamics in Children " The Foster Foundation Jan. 1, 2000 - Dec. 31, 2000
    "Pediatric AIDS Clinical Trials Group" NIH Feb. 1, 1999 - Jan. 31, 2000
    "Pediatric AIDS Emergency Funds" Elizabeth Glaser Pediatric AIDS Foundation Jan. 1, 1999 - Dec. 31, 2000
    "Viral Lymphocyte Dynamics in Children" The Foster Foundation Dec. 19, 1998 - Dec. 31, 1999
    "Monitoring the emergence of HIV-1 resistance to antiretroviral drugs in Latin America." World Health Organization (WHO/UNAIDS) Oct. 1, 1998 - Oct. 1, 1999
    "Immunizing by Mucosal SIV Exposure during RT Inhibition" NIH Sept. 30, 1998 - Sept. 29, 2001
    "Ryan White Titles I and IV" Seattle-King County Department of Public Health Aug. 1, 1997 - July 31, 2001
    "Pediatric AIDS Clinical Trials Group" NIH March 1, 1997
    "Pediatric AIDS Clinical Trials Group" NIH March 1, 1997
    "Transient HIV infection in infants." The Foster Foundation Dec. 19, 1996 - Dec. 18, 1998
    "Pediatric AIDS Clinical Trials Group" NIH Feb. 28, 1992 - Feb. 28, 1997
    “Academic Pediatric Infectious Disease” NIH $285,024 annual direct costs July 1981 - April 2023

Overview

Board Certification(s)

Pediatric Infectious Diseases
Pediatrics

Medical/Professional School

University of Kansas at Lawrence, Lawrence, KS
University of California Los Angeles, Los Angeles, CA

Residency

David Geffen School of Medicine at UCLA, Los Angeles, CA

Clinical Interests

Prevention and treatment of pediatric HIV disease, neonatal herpes simplex virus (HSV) and congenital cytomegalovirus (CMV) infections

Research Description

Over the past 30 years, our group has conducted research projects in Peru, Thailand, Mozambique, Kenya, Uganda and South Africa. In close concert with our collaborators our studies have aimed to address practical questions related to the prevention of HIV-1 infection in infants, mechanisms leading to shedding of virus in breast milk and genital tract of adults, treatment of drug-resistant virus in children and adults and understanding mechanisms underlying the persistence of HIV infection despite effective antiretroviral treatment. Additionally, we have developed economical assays with the goal of making testing accessible to resource-poor communities, to improve the management of HIV infection.

When studying transmitted resistance from HIV-infected mothers to their children, our group noted a series of errors that refuted the concept of transient HIV infection occurring in infants (Frenkel et al. Science, 1998; PMID9582120). Our findings in this study cemented the importance of meticulous Laboratory Quality Assurance in our research and clinical work. Our group has operated a CLIA Laboratory for >17 years primarily performing assays NIH IMPAACT Network.

Our laboratory located within SCRI found evidence and later provided proof that proliferating cells have a major role in sustaining the HIV reservoir despite effective treatment (J Virol 2005, PMID16014925) (Science 2014, PMID25011556Research Focus Area

Infectious Disease, Virology